Witte E H, Peters A A, Smit I B, van der Linden M C, Mouton R P, van der Meer J W, van Erp E J
Department of Gynecology and Reproduction, Leiden University Medical Center, The Netherlands.
Eur J Obstet Gynecol Reprod Biol. 1993 Jul;50(2):153-8. doi: 10.1016/0028-2243(93)90180-k.
A double-blind, randomised study was conducted to compare the efficacy and safety of a combination of pefloxacin and metronidazole versus doxycycline and metronidazole in patients with pelvic inflammatory disease (PID). The clinical diagnosis had to be confirmed by laparoscopy before patients were included. Of the 74 patients who fulfilled the clinical criteria for PID, laparoscopy confirmed the diagnosis in only 40 patients (54%). The microorganism most frequently found as causative pathogen was Chlamydia trachomatis. Both treatment groups showed a good response to the study-medication. At discharge 9 patients in the pefloxacin group (45%) were cured and 10 patients (50%) had improved. In the doxycycline group 7 patients (35%) were cured and 10 patients (50%) had improved. Obviously pefloxacin/metronidazole and doxycycline/metronidazole are equally effective in the treatment of PID.
进行了一项双盲随机研究，比较培氟沙星与甲硝唑联合用药和多西环素与甲硝唑联合用药治疗盆腔炎（PID）患者的疗效和安全性。在纳入患者之前，临床诊断必须通过腹腔镜检查来确认。在74例符合PID临床标准的患者中，只有40例（54%）经腹腔镜检查确诊。最常被发现为致病病原体的微生物是沙眼衣原体。两个治疗组对研究药物均显示出良好反应。出院时，培氟沙星组有9例患者（45%）治愈，10例患者（50%）病情改善。多西环素组有7例患者（35%）治愈，10例患者（50%）病情改善。显然，培氟沙星/甲硝唑和多西环素/甲硝唑在治疗PID方面同样有效。
